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Summary Background Dacomitinib (PF-00299804) is an
oral, irreversible, small molecule inhibitor of human
epidermal growth factor receptor-1, -2, and -4 tyrosine
kinases. Methods This phase I, open-label, dose-escalation
study (clinicaltrials.gov: NCT00783328) primarily evaluated
the safety and tolerability of dacomitinib by dose-limiting
toxicity (DLT), and determined the clinically recommended
phase II dose (RP2D) in Japanese patients with advanced solid
tumors. Dacomitinib was administered orally at three dose
levels (15, 30, or 45 mg once daily [QD]). Patients initially
received a single dose, and after 9 days of follow-up, contin-
uously QD in 21-day cycles. Endpoints included pharmaco-
kinetics (PK) and antitumor activity. Results Thirteen patients
were assigned to the three dose levels (15 mg cohort: n03;
30 mg cohort: n03; 45 mg cohort: n07) according to a
traditional ‘3+3’ design. None of the treated patients experi-
enced a DLT. Toxicities weremanageable and similar in type to
those observed in other studies. PK concentration parameters
increased with dose over the range evaluated, with no evidence
of accumulation over time. Of 13 evaluable patients, one with
NSCLC (adenocarcinoma) had a partial response and nine
patients had stable disease. Conclusions Dacomitinib 45 mg
QD was defined as the RP2D and demonstrated preliminary
activity in Japanese patients with advanced solid tumors.
Keywords Dacomitinib . PF-00299804 . Epidermal growth
factor receptor . Tyrosine kinase inhibitor . Japanese patients .
Phase I
Acknowledgment of research support: This study was sponsored by
Pfizer Inc.
Prior presentation: Takahashi T, Boku N, Murakami H, et al. First
report of the safety, pharmacokinetics, and preliminary activity of PF-
00299804 in Japanese patients with advanced solid tumors. Poster
presentation at the 35th Congress of the European Society for Medical
Oncology (ESMO), Milan, Italy, October 8–12, 2010
T. Takahashi :N. Boku :H. Murakami : T. Naito :A. Tsuya :






La Jolla, CA, USA




Division of Thoracic Oncology, Shizuoka Cancer Center,
1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun,
Shizuoka 411-8777, Japan
e-mail: t.takahashi@scchr.jp
Invest New Drugs (2012) 30:2352–2363
DOI 10.1007/s10637-011-9789-z
Introduction
The epidermal growth factor receptor (EGFR) is a mem-
brane receptor tyrosine kinase. EGFR belongs to the human
epidermal growth factor receptor (HER) family, comprising
the following four types of highly similar membrane recep-
tors: EGFR (HER1), HER2, HER3, and HER4 [1]. The role
of the HER family members in many cancer types is well
documented. One or more members of this receptor family
are expressed in over 90% of solid tumors, and approxi-
mately 60% of those tumors possess abnormalities in this
family that potentially contribute to their neoplastic pheno-
type [2, 3]. EGFR is activated by binding of selective
ligands, with subsequent receptor dimerization. This results
in autophosphorylation which is known to lead to the regu-
lation of various biological processes, including cell prolif-
eration, angiogenesis, invasion/metastasis, and suppression
of apoptosis [4]. The simultaneous activation of different
HER family members through dynamic hetero- and homo-
dimerization could compromise the therapeutic efficacy by
inhibition of a single receptor. Therefore, an inhibitor that
blocks the tyrosine kinase activity of the entire HER family,
and hence the signaling of both hetero- and homodimers,
could have a significant therapeutic effect, even in tumors
that have not previously responded to conventional single-
receptor inhibitors.
Dacomitinib (PF-00299804; Pfizer Inc., New York, NY,
USA) is an orally administered, highly selective irreversible
small molecule inhibitor of the HER family of tyrosine
kinases (HER1, HER2, and HER4) [5, 6]. In preclinical
human tumor xenograft models that express and/or over-
express HER family members, dacomitinib showed antitu-
mor effects. Antitumor effects were shown against tumors
with EGFR-activating mutations, found in 30–50% of Asian
patients with lung cancer [7], and also against tumors with
T790M, a mutation detected in the tumors of approximately
50% of patients with lung adenocarcinoma who develop
acquired resistance to gefitinib or erlotinib [8–10].
In a phase I, dose-escalation study [11], the safety of
dacomitinib (0.5–60 mg) was studied in Western patients
with advanced solid tumors. Dose-limiting toxicities (DLTs)
included stomatitis (n02; 1 each at 30 mg once daily [QD]
and 60 mg QD), rash (n02; at 45 mg QD), palmar–plantar
erythrodysesthesia syndrome, dehydration, and diarrhea in
the same patient (n01 at 60 mg QD). The maximum toler-
ated dose (MTD) was defined as the highest dose level at
which the proportion of patients with DLTs did not exceed
the protocol-defined rate of 33%. Thus, dacomitinib 45 mg
QD was determined as the MTD, and also chosen as the
clinically recommended phase II dose (RP2D). Subsequent
phase II studies have been conducted with a starting dose of
45 mg QD in advanced non-small cell lung cancer (NSCLC)
and in squamous cell cancer of the head and neck [12–14].
The aim of this phase I, open-label, dose-escalation study
(NCT00783328) was primarily to evaluate the safety and
tolerability of dacomitinib in Japanese patients with ad-
vanced solid tumors at doses up to the RP2D of 45 mg
QD, which had previously been determined in a Western
study [11, 15]. Secondary objectives were to evaluate the
pharmacokinetic (PK) profile of dacomitinib following sin-




Patients were aged 20–75 years (male or female), with histo-
logic or cytopathologic diagnosis of solid tumors. Other key
inclusion criteria included: Eastern Cooperative Oncology
Group (ECOG) performance status of 0/1; resolution of acute
toxicities caused by prior therapy or surgery to National
Cancer Institute Common Terminology Criteria for Adverse
Events (NCI CTCAE) version 3.0 grade 1; previous drug
treatment for cancer completed and no further treatment for
at least 3 weeks prior to initiation of study treatment; and
adequate organ function, including left ventricular ejection
fraction (LVEF) ≥50%.
Key exclusion criteria included: clinically significant ab-
normalities of the cornea; brain/central nervous system me-
tastases (symptomatic and/or requiring treatment); any
clinically significant gastrointestinal abnormalities; uncon-
trolled or significant cardiovascular disease; grade 3/4 diar-
rhea or skin rash toxicity and/or history of pneumonitis related
to treatment with a tyrosine kinase inhibitor; and requirement
for drugs that are highly dependent on cytochrome P450
(CYP) 2D6 for metabolism.
Study design and treatment
This was a phase I, open-label, dose-escalation study. Daco-
mitinib was administered at three dose levels (15, 30, and
45 mg) orally. After single-dose administration, and 9 days of
follow-up, dacomitinib was given continuously QD in 21-day
cycles. Treatment was repeated in 21-day cycles until progres-
sion, unacceptable toxicity, or withdrawal of patient consent.
A traditional 3+3 dose-escalation design was used to es-
calate dacomitinib 15 mg QD to 45 mg QD, and an additional
three patients were enrolled into the 45-mg cohort for the
safety analysis. Dose interruptions or reductions were permit-
ted in patients experiencing grade 3/4 toxicity, with treatment
resumed at the same or next lowest dose level upon adequate
recovery (grade ≤1). Tolerability was evaluated according to
the type and frequency of DLTs observed from single-dose
administration to day 21 of the first cycle of continuous
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dosing. DLTs were defined as: grade ≥3 non-hematologic
toxicity uncontrollable with standard supportive care; delayed
recovery from toxicity related to dacomitinib treatment which
postponed scheduled retreatment for >14 days; patients unable
to take at least 50% of planned doses due to toxicity related to
dacomitinib; grade 4 neutropenia or febrile neutropenia; and
grade 4 thrombocytopenia (<25,000 cells/mm3) or bleeding
requiring a platelet transfusion.
If a patient’s dose was delayed due to a DLT, treatment
could be resumed at the next lowest dose level. Dose reduc-
tions (two dose reductions for patients treated at 30 mg QD,
one dose reduction for patients treated at 15 mg QD) were
permitted. However, if a dose was delayed due to toxicity
for ≥21 days, treatment was not to be resumed and the
patient was withdrawn from the study.
This study was conducted in compliance with the ethical
principles originating in or derived from the Declaration of
Helsinki and in compliance with all International Confer-
ence on Harmonization (ICH) Good Clinical Practice (GCP)
Guidelines. In addition, all local regulatory requirements
were followed, in particular, those affording greater protec-
tion for the safety of trial participants. The final protocol,
any amendments, and informed consent documentation
were reviewed and approved by the Institutional Review
Board at the Shizuoka Cancer Center. The study was con-
ducted at one center in Japan. All patients provided written,
signed informed consent prior to entry into the trial.
Assessments and analysis
LVEF, slit lamp ophthalmologic examination, vital signs,
ECOG performance status, laboratory tests (hematology,
blood chemistry, coagulation, and urinalysis), chest X-ray,
and electrocardiogram were performed at baseline and at
regular intervals throughout the study. Safety was assessed
according to CTCAE version 3.0.
Analyses for detection of HER1 and KRAS mutations in
tumor tissue were performed as optional at baseline. Tumor
assessments were performed at baseline, cycle 2, cycle 4,
and every 6 weeks thereafter. Evaluation of antitumor activ-
ity was based on objective tumor assessments using Re-
sponse Evaluation Criteria in Solid Tumors (RECIST)
version 1.0 [16].
Evaluation of best overall response (BOR) was deter-
mined as the most favorable overall response confirmed as
partial response (PR) or complete response (CR) during the
treatment period, or as stable disease (SD) if a response of
SD, PR or CR was achieved without subsequent confirma-
tion at a response evaluation at least 6 weeks after initiation
of multiple-dose administration. An evaluation of PR or CR
required that changes in tumor measurements were con-
firmed by repeated assessments performed no less than
4 weeks after the criteria for the response had first been met.
Pharmacokinetic assessments
Serial blood samples for PK assessment were collected after
a single dose on any day between 9 and 1 days prior to the
start of continuous dosing (referred to as D-9 throughout
this manuscript), and on day 14 of cycle 1 (C1D14; steady
state). Pre-dose blood samples were collected on day 1 of
cycles 2–4 (plasma trough concentrations [Ctrough]). Plasma
samples were analyzed for dacomitinib concentrations at
Alta Analytical Laboratory (El Dorado Hills, CA, USA)
using a validated analytical assay (validated, sensitive, and
a specific high-performance liquid chromatography tandem
mass spectrometric method [LC/MS/MS]) in compliance
with Pfizer standard operating procedures.
Pharmacokinetic parameters were derived from dacomiti-
nib plasma concentration after single and multiple dosing
using non-compartmental analysis. For single-dose adminis-
tration (D-9), the following PK parameters were calculated:
maximum plasma concentration (Cmax), time to maximum
plasma concentration (Tmax), terminal half-life (t1/2), area
under the plasma concentration–time curve from 0 to 24 h
after a single dose (AUC24), the area under the plasma con-
centration–time curve from 0 to infinity (AUCinf), and clear-
ance (CL). For multiple-dose administration (C1D14), the
following PK parameters were calculated: Cmax, Tmax, CL,
area under the plasma concentration–time curve from 0 to 24 h
at steady state (AUCτ), trough concentration (Ctrough), mean
plasma concentration (Cave), accumulation ratio (Rac, the ratio
of AUCτ to AUC24), and the linearity ratio (Rss, the ratio of
AUCτ to AUCinf).
For both single- and multiple-dose administration, descrip-
tive statistics were calculated (arithmetic mean, standard de-
viation, coefficient of variation, median, and geometric mean).
Trough concentration data from cycle 2 day 1, cycle 3 day 1,
and cycle 4 day 1 were analyzed together with the trough
concentration data from cycle 1 day 14 to assess whether the
PK steady-state had been achieved.
Dynamic model of tumor size
Change in size of tumor target lesions over time was
recorded as the sum of the longest dimensions; all target
lesions were measured using spiral computed tomogra-
phy (CT) or magnetic resonance imaging (MRI) accord-
ing to RECIST version 1.0 [16]. The longitudinal tumor
size data were analyzed using nonlinear mixed effect
models (NONMEM® 7.12, Globomax). The time course
of tumor growth was described using two parameters based on
a previous report [17]: shrinkage rate (SR) following an ex-
ponential tumor growth decline, and a linear progression rate
growth (TPR):
TSi tð Þ ¼ BASEi:eSRi:t þ TPRi:t
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where TSi(t) is the tumor size at time t for the ith individual,
Basei is the observed individual tumor size at baseline, SRi is
the tumor shrinkage rate constant, and TPRi is the linear tumor
progression rate.
Inter-individual variability (IIV) was accounted for in the
population mean parameters using an exponential error
model:
θi ¼ θ  eηi
where θi is the individual parameter estimate, θ is the mean
population value of the parameter (SR or TPR), and η is a
random variable to describe the IIV. The IIV has a normal
probability distribution, with a mean of 0 and variance ω2.
The estimates of IIV were presented as standard deviations
calculated as √ω2.
The residual variability was modeled using a homosce-
dastic, exponential error model of the form:
Yij ¼ Fij  e"ij
where Yij is the observed data for the ith individual at
time tj, Fij is the prediction based on the pharmacody-
namic model, and εij is the exponential error that is a
normally distributed random variable with a mean of 0 and
variance σ2.
The purpose of this tumor model analysis was to explore
the potential effect of several covariates on tumor growth
parameters (dose, gender, baseline ECOG, and EGFR mu-
tation status). Full model development involved testing for
covariates (both continuous and categorical) with the goal of
explaining inter-individual variability and improving predic-
tive performance.
Parameterization of covariate models was guided by ex-
amination of the plots of the ηs on SR and TPR versus
covariates (gender, ECOG PS, dose cohort, and EGFR mu-
tation status) from the final base model.
Dichotomous covariates were modeled as follows:
θ ¼ θ0  ð1þ θx  xÞ
Table 1 Patient characteristics
at baseline
ECOG PS Eastern Cooperative
Oncology Group Performance
Status; EGFR epidermal growth
factor receptor
aStage IV NSCLC except for one
patient in the 30 mg cohort with
stage IIIB NSCLC and one pa-
tient in the 15 mg cohort with
SCLC
Dacomitinib
15 mg QD (n03) 30 mg QD (n03) 45 mg QD (n07)
Age, years
Median (range) 56.0 (55–70) 66.0 (64–71) 65.0 (36–69)
Male/female, n (%) 2/1 (66.7/33.3) 1/2 (33.3/66.7) 2/5 (28.6/71.4)
ECOG PS, n (%)
0 1 (33.3) 1 (33.3) 3 (42.9)
1 2 (66.7) 2 (66.7) 4 (57.1)
Smoking classification, n (%)
Never 1 (33.3) 2 (66.7) 4 (57.1)
Smoker 0 1 (33.3) 1 (14.3)
Ex-smoker 2 (66.7) 0 2 (28.6)
Malignancy, n (%)
Breast (stage IV) – 1 (33.3) –
Colon (stage IV) – – 2 (28.6)
Lunga 3 (100) 2 (66.7) 4 (57.1)
Metastatic neoplasm (stage IV) – – 1 (14.3)
EGFR mutation, n (%)
Positive 1 (33.3) 1 (33.3) 1 (14.3)
Wild-type 0 0 3 (42.9)
Not done 2 (66.7) 2 (66.7) 3 (42.9)
KRAS mutation, n (%)
Positive 0 0 2 (28.6)
Wild-type 0 0 1 (14.3)
Not done 3 (100) 3 (100) 4 (57.1)
Prior treatment, n (%)
Surgery 0 1 (33.3) 3 (42.9)
Radiotherapy 2 (66.7) 1 (33.3) 1 (14.3)
Chemotherapy 3 (100) 3 (100) 7 (100)
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where θ0 denotes the population value of the parameter for
the null value of the covariate x (i.e. x00). The parameter θx
denotes the fractional change in θ0 when x01.
A full-model approach was performed after the selection of
the covariates based on the assessment of the ηs plots or
assessment of the individual parameter estimates versus the
covariates of interest. The final model was constructed after
removing all covariates that were not statistically significant
(e.g. a00.01) and also those covariates that did not have a
clinically significant effect.
Results
Patient characteristics and disposition
Thirteen patients were enrolled across three dacomitinib dose
levels: 15 mg QD, n03; 30 mg QD, n03; 45 mg QD, n07.
The most common tumor type in the 13 treated patients was
NSCLC (n09, 69%). All patients were Japanese; baseline
characteristics are summarized in Table 1.
Themedian number of cycles received at 15, 30, and 45mg
QD was 2 (range, 1–37), 6 (range, 4–9), and 6 (range, 1–13),
respectively.
All 13 patients were finally withdrawn from the study; the
most common reason for discontinuation was disease progres-
sion (n010). Other reasons were global deterioration (n02)
and adverse event (AE) (rash; n01). One patient in the 45 mg
cohort required dose reduction due to AE (grade 2 rash).
Safety and tolerability
One patient in the 45 mg cohort was excluded from the DLT
analysis set due to poor treatment compliance (28.6% of
planned doses received) in cycle 1 of multiple-dose admin-
istration due to disease progression. DLT was evaluated in
the other 12 patients. There were no DLTs observed at any
dose during the DLT evaluation period.
Adverse events were generally of grade 1/2 severity
and manageable with standard supportive care. There
were no grade 4 AEs reported. One grade 5 AE oc-
curred in a patient in the 15 mg cohort; this was not
Table 2 Number of patients with treatment-related adverse events by maximum CTCAE gradea (occurring in ≥2 patients in all cycles)
AE 15 mg QD (n03) 30 mg QD (n03) 45 mg QD (n07) Total (N013)
All G1 G2 G3 All G1 G2 G3 All G1 G2 G3
Rash 3 2 1 0 3 1 2 0 7 1 4 2 13 (100%)
Diarrhea 2 2 0 0 3 3 0 0 7 4 3 0 12 (92%)
Paronychia 1 0 1 0 2 0 2 0 6 1 5 0 9 (69%)
Dry skin 2 1 1 0 1 0 1 0 5 5 0 0 8 (61.5%)
Stomatitis 1 1 0 0 2 1 1 0 5 4 1 0 8 (61.5%)
Fatigue 0 0 0 0 1 0 1 0 5 1 4 0 6 (46%)
Palmar–plantar erythrodysesthesia 1 1 0 0 2 0 2 0 2 0 2 0 5 (38%)
Cheilitis 2 2 0 0 1 1 0 0 2 2 0 0 5 (38%)
Conjunctivitis 0 0 0 0 1 1 0 0 3 3 0 0 4 (31%)
Leukopenia 0 0 0 0 0 0 0 0 3 1 2 0 3 (23%)
Proteinuria 0 0 0 0 0 0 0 0 3 2 1 0 3 (23%)
Nausea 0 0 0 0 1 1 0 0 2 1 1 0 3 (23%)
Weight decreased 0 0 0 0 1 0 1 0 2 0 2 0 3 (23%)
Decreased appetite 0 0 0 0 1 0 1 0 2 0 1 1 3 (23%)
Edema 0 0 0 0 0 0 0 0 2 1 1 0 2 (15%)
Hematuria 0 0 0 0 0 0 0 0 2 2 0 0 2 (15%)
Hypertrichosis 0 0 0 0 0 0 0 0 2 2 0 0 2 (15%)
Skin fissures 0 0 0 0 0 0 0 0 2 1 1 0 2 (15%)
ECG QT prolonged 2 1 1 0 0 0 0 0 0 0 0 0 2 (15%)
Alanine aminotransferase increased 0 0 0 0 0 0 0 0 2 0 1 1 2 (15%)
Aspartate aminotransferase increased 0 0 0 0 0 0 0 0 2 0 1 1 2 (15%)
Blood bilirubin increased 0 0 0 0 0 0 0 0 2 0 1 1 2 (15%)
ECG electrocardiogram; G grade
a There were no grade 4 or 5 treatment-related adverse events
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considered related to the study drug. This patient died
of respiratory failure due to disease progression 25 days
after the last dose of study drug. Most common all-
causality AEs across all dose levels were rash (n013),
diarrhea (n012), paronychia (n09), dry skin (n08),
stomatitis (n08), and fatigue (n06).
Fig. 1 Mean (SD) plasma
concentration–time profiles of
dacomitinib following single
(panel a; D-9) and multiple
(panel b; C1D14) dosing
Table 3 Preliminary mean (%CV) dacomitinib plasma pharmacokinetic parameters following single (D-9) and multiple dosing (C1D14)
Single dose (D-9)







t1/2 (h) CL/F(L/h) *Rss
b
15 3 24 (6.0–24.0) 8.0 (31) 9.48 (39) 660.3 (25) 61.1 (25) 23.7 (26) 1.12 (0.95–1.31)
30 3 8 (8.0–24.0) 12.2 (55) 6.52 (51) 987.5 (33) 98.0 (45) 32.0 (34) 1.39 (1.18–1.62)
45 7 6 (4.0–24.0) 21.2 (71) 7.98 (58) 1,604 (31) 80.0 (15) 30.4 (32) 1.21 (1.10–1.33)
Multiple dose (C1D14)














15 2e 15 (6.0–24.0) 32.0 (11) 28.2–33.2 29.7 (17) 713 (17) 21.4 (17) 6.32 (4.73–8.45)
30 3 4 (0.0–8.0) 64.3 (19) 49.0–56.5 56.3 (22) 1,353 (21) 22.9 (22) 7.37 (2.82–19.28)
45 6 8 (4.0–8.0) 81.2 (21) 60.9–76.6 75.1 (23) 1,803 (20) 26.1 (23) 6.37 (4.91–8.27)
AUCinf area under the concentration–time curve from time zero to infinity; AUCτ AUC over the dosing interval at steady state; Cmax maximum
plasma concentration; Cavemean plasma concentration at steady state; Ctrough trough plasma concentration; CL/F clearance; Rac accumulation ratio;
Rsslinearity ratio; t1/2 terminal half-life; Tmax time to Cmax; %CV percentage coefficient of variation; QD once daily
aMedian (min, max); b AUCτ/AUCinf;
c range (min, max) of averaged Ctrough concentrations from Day 1 of Cycles 2 to 4;
d AUCτ/AUC24;
e for
n02, parameters are presented as mean (min, max); * geometric mean ratio and 90% confidence interval
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Table 2 lists treatment-related AEs (TRAEs) by grade
occurring in ≥2 patients in all cycles. Overall, there were
eight treatment-related grade 3 AEs: one in the 15 mg
cohort: transient ischemic attack; and seven in the 45 mg
dosing cohort: rash (n02), device-related infection, decreased
appetite, alanine aminotransferase increased, aspartate amino-
transferase increased, and blood bilirubin increased (each
n01). AEs observed in ≥8 of 13 patients (≥61.5%) were rash
(n013), diarrhea (n012), paronychia (n09), dry skin (n08),
and stomatitis (n08). AEs observed in ≥1 patient during the
single-dose administration phase of dacomitinib were rash and
diarrhea.
No patient had an absolute change of ≥500 ms or a
≥60 ms change from baseline in QTc, QTcB, or QTcF
interval. Two cases of change in QT interval were recorded
as AEs; one patient (15 mg cohort) experienced a prolonged
QT interval (grade 2) 8 days after being discontinued from
study due to disease progression, and another patient (15 mg
cohort) had a prolonged QTcF interval (26 ms from baseline;
grade 1) at day 1 cycle 1, but was not considered to have
clinically significant changes.
There were two serious AEs (SAEs) considered by inves-
tigators to be possibly related to the study drug, both in the
45mg dose cohort; one case of hemobilia occurred in a patient
with liver metastases shown to have progression on imaging at
day 6 cycle 1—the drug was temporarily withdrawn and the
patient recovered. The other SAE was an instance of device-
related infection (an episode of bacteremia following catheter
placement at a skin site involved with a treatment-induced
skin reaction). One patient permanently discontinued the
Table 4 Summary of profiles for patients with NSCLC (n08) and reductions in tumor size
















1 70 years (M) Adenocarcinoma 1. Carboplatin+
paclitaxel
15 25.20 M / 767 D PR −57.7% Exon 19 del Objective
progression
or relapse2. Docetaxel
2 55 years (F) Adenocarcinoma 1. Carboplatin+
paclitaxel
















4 66 years (F) Adenocarcinoma 1. Carboplatin+
paclitaxel
































8 65 years (M) Adenocarcinoma 1. Carboplatin+
paclitaxel





PD progressive disease; PR partial response; SD stable disease
a (Sum of the largest diameters – Sum of the largest diameters at baseline) / (Sum of the largest diameters at baseline)×100
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study due to a TRAE (grade 2, treatment-related rash). Rash
was first reported on day 14 of cycle 1, and the patient
discontinued on day 1 of cycle 6 before progressive disease.
There were no deaths during the study.
Temporary discontinuations due to TRAEs were required
by five patients (all in the 45 mg dosing cohort); grade 3
rash occurred in two patients, and the remaining AEs were
of grade 2 severity. One patient with a rash required a dose
reduction from 45 mg to 30 mg.
Pharmacokinetics
Mean plasma concentration–time profiles and PK parame-
ters for dacomitinib following single (D-9) and multiple
(C1D14) dosing are shown in Fig. 1 and Table 3.
Following single oral dose administration (D-9), median
Tmax ranged from 6 to 24 h over a dose range of 15–45 mg.
The mean values for the PK parameters representing
systemic exposure in rate (Cmax) and extent (AUCinf)
increased along with dose in a proportional manner.
Dose-proportionality was confirmed by consistency in
the mean values for dose-normalized Cmax and AUCinf
across the dose range studied. Mean apparent clearance
ranged from 23.7 to 32 L/h across the 15–45 mg dose
levels.
Mean Cmax and AUCτ increased after multiple dosing
(C1D14). The geometric mean accumulation ratio ranged
from 6.32 to 7.37 over the dose range. These calculated values
are within an anticipated range based on the estimated half-life
of dacomitinib and the daily dosing schedule. The linearity
ratio was close to 1 across the studied dose levels. These
reported parameters suggest that dacomitinib has linear kinet-
ics after single- and multiple-dose administration in the dose
range studied.
Fig. 2 Pre- and post-treatment
computed tomography: a 70-
year-old patient with NSCLC
(Table 4, patient No. 1) (a) re-
ceiving dacomitinib at 15 mg
QD; and a 66-year-old patient
with NSCLC (Table 4, patient
No. 4) (b) receiving dacomiti-
nib at 30 mg QD
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Antitumor activity
Of 13 evaluable patients, one experienced a PR as a BOR
per RECIST. The PR (treatment duration 767 days) was
observed in a patient with NSCLC (adenocarcinoma, male,
70 years) in the 15 mg cohort (Table 4, Fig. 2a). No patient
had a CR. SD (≥6 weeks) was observed in nine patients:
three in the 30 mg QD cohort and six in the 45 mg QD
cohort (NSCLC, n06; colorectal carcinoma, n01; breast
cancer, n01; squamous cell neoplasm, n01). One patient
with SD (28.7% reduction) was a 66-year-old never-
smoking female who, following a PR on gefitinib, was
found via analysis of pleural effusion to have adenocarcino-
ma of lung characterized by both L858R and secondar-
yT790M mutations; she started dacomitinib 30 mg 79 days
after discontinuation of gefitinib and continued for 134 days
(8 cycles) before progression (Fig. 2b). Progressive disease
(PD) was observed in three patients (15 mg QD cohort, n0
2; 45 mg QD cohort, n01). Four of eight patients with
NSCLC had tumor size reductions (Table 4).
Tumor growth model
The model of tumor growth with the parameters for shrink-
age and progression rates fitted the data for tumor size fairly
well (Fig. 3). The observations versus population and indi-
vidual predictions were uniformly and closely distributed
around the line of identity. Table 5 lists the parameter and
precision estimates. The covariate analysis identified that
the shrinkage rate was significantly affected by EGFR mu-
tation status. Figure 4 shows the individual model parameter
estimates plots versus gender, ECOG status, dose level, and
EGFR mutation status for the base model (without any
covariates) and final model (EGFR on shrinkage rate).
Shrinkage rate was 85% less in EGFR wild type versus
EGFR mutant subjects. For the 15 mg cohort, although the
variability around individual SR and TPR parameters was
larger than for the other two dose groups, the available
data did not support the addition of dose cohort as
covariate, probably due to the small sample size evalu-
ated in this study. No correlation with duration of treat-
ment, progression-free survival, or overall survival was
undertaken at this time.
Discussion
This is the first report of the safety, PK profile, and antitumor
activity of dacomitinib in Japanese patients with advanced
solid tumors.
Treatment with dacomitinib in phase I and II studies of
Western and Korean patients with advanced solid tumors
has previously been associated with an acceptable safety
profile and evidence of preliminary activity [11–13, 18].
The RP2D was established as 45 mg QD (given continuously
in 21-day cycles) in these patient populations.
Fig. 3 Observed tumor size
versus population and
individual predictions
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Dacomitinib appeared to be generally well tolerated in
Japanese patients; the safety profile was consistent with that
observed in Western and Korean studies [11–13, 18]. There
were no DLTs observed at any dose, and AEs were generally
of grade 1/2 severity and manageable. No grade 4 AEs were
reported. Most common AEs (primarily skin and gastroin-
testinal toxicities of rash, diarrhea, paronychia, stomatitis,
and dry skin) were consistent with the toxicities of other
EGFR tyrosine kinase inhibitors [19–21]. For comparison,
the most commonly reported AEs in the phase II dacomiti-
nib versus erlotinib study of advanced NSCLC [13] were
diarrhea, dermatitis acneiform, stomatitis, mucosal inflam-
mation, and paronychia; similarly, the Korean phase I/II
study in refractory NSCLC [18] reported diarrhea, dermati-
tis acneiform, paronychia, and stomatitis as the most com-
mon AEs. In each of these studies, AEs were primarily of
grade 1 or 2 severity and manageable with standard sup-
portive care.
Dacomitinib systemic exposure increased with increasing
dose in this study, and the evaluated parameters suggested
linear PK after both single- and multiple-dose administra-
tion over the dose range studied. PK exposure parameters
for dacomitinib appeared to be comparable between the
Fig. 4 Individual variability in parameter estimates (ETA) for SR and TPR versus gender, ECOG status, dose group, and EGFR mutation status for
the final model with EGFR on SR as covariate (left) and base model with no covariates added (right)
Table 5 Parameter and precision estimates in the tumor growth model
Parameter Value RSE (%) IIV Shrinkage (%)
θSR (day
-1) 0.063 52.3 76 5.48
θTPR (cm/day) 0.187 41.3 58 5.49
θmutation.on.SR −0.85 9 – –
σ 0.084 13 – 9.08
IIV inter-individual variability; RSE relative standard errors; θSR mean
population value for shrinkage rate; θTPR mean population value for
tumor progression rate; θmutation.on.SR mean population value for EGFR
mutation on shrinkage rate; σ residual variability
Invest New Drugs (2012) 30:2352–2363 2361
Japanese patients evaluated in this study and patients in-
cluded in two separate study populations (A7471003,
Korean patients with advanced NSCLC; and A7471001,
Western patients with advanced solid malignancies) [11,
18]. In the Korean study, dacomitinib showed linear kinetics
at the doses studied and the PK parameters were similar to
those previously observed in Western populations after
single- and multiple-dose administration. For example, sub-
stantial overlap was seen in the AUCtau between Asian and
Western patients after multiple dosing at 30 mg QD and
45 mg QD [22].
While these data are limited by the small sample
size, antitumor activity was suggested in these Japanese
patients. One of eight patients with NSCLC achieved a
PR and six patients experienced SD (≥6 weeks) as best
response. One patient with NSCLC (adenocarcinoma,
ex-smoker, male, 70 years [Table 4]) who had an exon
19 deletion and who was EGFR tyrosine kinase inhib-
itor treatment-naïve experienced a PR (57.7% reduction)
as best response following treatment with dacomitinib
15 mg QD, and had an extended treatment duration of
25 months (767 days) (Fig. 2a). One further patient
with NSCLC, with an exon 21 mutation (L858R) and
T790M secondary mutation, had sustained SD (179 days,
28.7% reduction) (Fig. 2b). Approximately 50% of the
acquired resistance to EGFR tyrosine kinase inhibitors
such as gefitinib and erlotinib has been considered to be
due to the presence of the T790M EGFR mutation [23]
and, as treatment with pan-HER inhibitors (such as
dacomitinib, afatinib, and neratinib) has not previously
been reported to be beneficial in patients with known
T790M resistance, the degree of benefit observed in this
patient is noteworthy.
Antitumor activity in early clinical studies is generally
evaluated using objective response rate or progression-free
survival. However, in typical small, non-comparative phase
I or II studies, these estimates are generally imprecise and do
not effectively inform ‘go, no-go’ decisions and the subse-
quent design of phase III clinical trials. In addition, change
in tumor size can be seen as a biomarker of drug effect that is
further predictive of a clinical endpoint (i.e. survival). There is
clearly a need for additional quantitative approaches to im-
prove success rates in oncology drug development, consistent
with recent Food and Drug Administration initiatives [24, 25].
The exploratory dynamic tumor growth model analysis
performed in this study [26] provides support for the
importance of molecular markers in patient selection for
treatment with targeted agents. In the present study, this
model confirmed a better response to dacomitinb in
EGFR mutant compared with EGFR wild-type tumors,
although no other markers were identified to be related
to response. The small sample size in this study pre-
cluded identification of other markers, but further tumor
growth analyses, using pooled data from several dacomi-
tinib trials, could enable us to better explore the impact of
dacomitinib exposure and other covariates such as KRAS
mutant status, race, etc., on response to treatment. Moreover,
by modeling tumor growth patterns we may be better able to
understand differences between irreversible and reversible
tyrosine kinase inhibitors.
In conclusion, this first report of dacomitinib in Japanese
patients with advanced solid tumors suggests that the treat-
ment is well tolerated and has potential for therapeutic benefit
in Japanese patients. Safety and PK data were consistent with
previous clinical experience in Western and Korean patients
with advanced malignancies. Antitumor activity was also
suggested, particularly in NSCLC where efficacy has previ-
ously been shown in other phase I and II clinical trials in
refractory NSCLC and in a randomized phase II study versus
erlotinib in second-/third-line treatment [11, 13, 18, 27]. On
the basis of these data, phase III clinical trials of dacomitinib
are ongoing in two settings of advanced NSCLC: after failure
of one or two prior chemotherapy regimens and prior EGFR
tyrosine kinase inhibitor therapy (NCT01000025), and after
failure of one (and no more than two) prior chemotherapies
versus erlotinib (NCT01360554). Both studies include collec-
tion of tissue for analysis of key molecular markers that may
be predictive of benefit, including EGFR and KRAS, and
include an analysis of data for East Asian versus other patients
as a stratification factor.
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